Get the Stockscreener App
0.55
3.40%
0.0183
X 4 Pharmaceuticals Inc stock is traded at $0.55, with a volume of 979.96K.
It is up +3.40% in the last 24 hours and down -11.49% over the past month.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$0.5317
Open:
$0.5
24h Volume:
979.96K
Relative Volume:
0.93
Market Cap:
$89.59M
Revenue:
-
Net Income/Loss:
$-101.17M
P/E Ratio:
-0.5288
EPS:
-1.04
Net Cash Flow:
$-96.57M
1W Performance:
+10.51%
1M Performance:
-11.49%
6M Performance:
-52.19%
1Y Performance:
-41.86%
1-Day Range:
$0.50
$0.5522
1-Week Range:
$0.496
$0.5522
52-Week Range:
$0.4721
$1.60
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition - Quantisnow
Top 50 Pharma: Oncology patent leaders 2024 - Drug Discovery & Development
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - Quantisnow
H.C. Wainwright reiterated coverage on Viking Therapeutics with a new price target - Quantisnow
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors - The Manila Times
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024 - PR Newswire
Sun Pharma shares tumble 4% as US court blocks Leqselvi launch - The Economic Times
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - The Manila Times
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - cnhinews.com
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - The Bakersfield Californian
Hypothyroidism Market to Expand by USD 789.8 Million (2024-2028) as New Drug Approvals Drive Revenue; Report Highlights AI's Role in Market TransformationTechnavio - The Malaysian Reserve
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting - Business Wire
MIRA Pharma up 27% on ketamine analogue’s preclinical results for chemotherapy pain - Mugglehead
Acute Respiratory Distress Syndrome (ARDS) Market Statistics, Emerging Trends, Key Drivers And Forecast To ... - WhaTech
SEC Form 424B5 filed by Eledon Pharmaceuticals Inc. - Quantisnow
SG Americas Securities LLC Makes New Investment in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Block Deal Today: Pharma stock tanks 4% after stake sale worth Rs 3,000 crore by promoter - ET Now
Innovations in Pediatric Bladder Treatment: Shaping a Healthier Future As Discussed In New Market Research ... - WhaTech
Cyclic Heavy Menstrual Bleeding Market Advancements Highlighted by Research And Strategies For Expansion 20... - WhaTech
Acromegaly Market Innovations Investigated by Size, Share, Trends And Outlook Report 2024-2033 - WhaTech
Duchenne Muscular Dystrophy Therapeutics Market Trends, Growth Insights, and Forecasts 2033 - WhaTech
Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52% - Simply Wall St
Pituitary Dwarf Treatment Global Market Overview In Latest Study - WhaTech
Report Probes the Iron Deficiency Injectable Global Market Research - WhaTech
Basal Cell Carcinoma Treatment Market Analysis, Advancements, and Growth Potential - WhaTech
Alopecia Market Key Trends, Latest Insights, Future Trends And Forecast To 2033 - WhaTech
The Evolution of Narcotic Drugs: Trends and Market Insights In New Report - WhaTech
X4 Pharmaceuticals (NASDAQ:XFOR) vs. Tectonic Therapeutic (NASDAQ:TECX) Critical Analysis - Defense World
Russia is getting Nvidia AI chips from an Indian pharma company - The Times of India
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting - The Manila Times
Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Size, Share And Forecast To 2033 - WhaTech
Director Singleton J Matthew exercised 16,000 shares at a strike of $4.48 and sold $1,272,000 worth of shares (16,000 units at $79.50) (SEC Form 4) - Quantisnow
Pack-Smart Inc. to Showcase innovative Delta-X Solutions for Pharmaceutical Supply Chains at PACK EXPO International 2024 - Healthcare Packaging
Global WHIM Syndrome Management Market Projected to Reach USD 17.91 Million by 2033 with a Strong CAGR of 6% - PharmiWeb.com
Malignant Melanoma Treatment Market 2024Industry Size, Business Segments, Innovative Strategies And Outl... - WhaTech
Q3 2024 update: patent activity in the pharmaceutical industry - Pharmaceutical Technology
X4 Pharmaceuticals to Report Third-Quarter 2024 Financial - GlobeNewswire
X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024 - The Manila Times
VRTX: 3 Pharma Stocks to Watch as Gene Therapy Gains Momentum - StockNews.com
Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
Ionis to hold third quarter 2024 financial results webcast - Quantisnow
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - Quantisnow
Renal Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
Atypical Chemokine Receptor 3 Market to Drive Growth with - openPR
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis - Quantisnow
Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer - PR Newswire
EVP Research Swayze Eric converted options into 125 shares and sold $2,031 worth of shares (53 units at $38.31) (SEC Form 4) - Quantisnow
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):